Indivior CLO vests 79,893 performance shares

Indivior Pharmaceuticals, Inc. Chief Legal Officer Jeffrey W. Burris reported the vesting of performance stock units on March 3, 2026.

Rhea-AI Filing Summary

Indivior Pharmaceuticals, Inc. Chief Legal Officer Jeffrey W. Burris reported the vesting of performance stock units on March 3, 2026. The units vested after performance conditions were determined to be met at 76.6%, resulting in 79,893 common shares vesting from a 104,300 target grant made on March 3, 2023. Each performance stock unit corresponded to one share of common stock. To cover tax withholding obligations from this vesting, 36,032 shares of common stock were disposed of at a price of $31.98 per share, leaving Burris with 71,518 directly owned common shares after these transactions.

Insider Trade Summary

104,300 shares exercised/converted

Exercise 3 txns

Insider Burris Jeffrey W

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Exercise	Performance Stock Units	104,300	$0.00	$0.00
Exercise	Common Stock	79,893	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	36,032	$31.98	$1.15M

Holdings After Transaction: Performance Stock Units — 0 contracts (Direct); Common Stock — 71,518 shares (Direct)

Footnotes (3)

1. F1. Represents the vesting of performance stock units upon the determination that the performance conditions were met at 76.6% with respect to the performance stock units granted to the Reporting Person on March 3, 2023, of which 79,893 shares vested out of the 104.300 target amount.
2. F2. Each performance stock unit represents a contingent right to receive one share of the Issuer's common stock.
3. F3. Shares used to satisfy tax withholding obligations associated with the vesting of performance stock units on March 3, 2026.

FAQ

What insider transactions did Indivior (INDV) report for Jeffrey W. Burris?

Indivior reported that Chief Legal Officer Jeffrey W. Burris had performance stock units vest on March 3, 2026. This vesting converted units into 79,893 common shares, with a portion of the shares subsequently disposed of to satisfy tax withholding obligations.

How many Indivior (INDV) shares vested for Jeffrey W. Burris in this Form 4?

The filing shows 79,893 shares of Indivior common stock vested for Jeffrey W. Burris. These shares came from performance stock units granted on March 3, 2023, where performance conditions were achieved at 76.6% of a 104,300 target amount.

What was the purpose of the 36,032-share disposition in the Indivior (INDV) Form 4?

The 36,032 Indivior common shares were disposed of to satisfy tax withholding obligations tied to the vesting of performance stock units on March 3, 2026. The shares were valued at $31.98 per share for this tax-related disposition.

What type of securities were involved in Jeffrey W. Burris’s Indivior (INDV) Form 4?

The transactions involved performance stock units and Indivior common stock. Performance stock units represented a contingent right to receive one share of common stock each, and their vesting triggered the issuance of 79,893 common shares to Jeffrey W. Burris.

How many Indivior (INDV) shares does Jeffrey W. Burris own after these Form 4 transactions?

After the reported transactions, Jeffrey W. Burris directly owns 71,518 shares of Indivior common stock. This figure reflects the conversion of performance stock units and the tax-withholding disposition of 36,032 shares on March 3, 2026.

What performance level was achieved for Jeffrey W. Burris’s Indivior (INDV) performance stock units?

The performance stock units vested after performance conditions were determined to be met at 76.6%. As a result, 79,893 shares vested out of the 104,300 target amount originally granted to Jeffrey W. Burris on March 3, 2023.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 03:59 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burris Jeffrey W

(Last) (First) (Middle)

10710 MIDLOTHIAN TURNPIKE

SUITE 125

(Street)

NORTH CHESTERFIELD VA 23235

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Indivior Pharmaceuticals, Inc. [ INDV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		M		79,893(1)	A	(2)	107,550	D
Common Stock	03/03/2026		F		36,032(3)	D	$31.98	71,518	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Stock Units	$0(2)	03/03/2026		M			104,300	03/03/2026(1)	(1)	Common Stock	104,300	(2)	0	D

Explanation of Responses:

1. Represents the vesting of performance stock units upon the determination that the performance conditions were met at 76.6% with respect to the performance stock units granted to the Reporting Person on March 3, 2023, of which 79,893 shares vested out of the 104.300 target amount.

2. Each performance stock unit represents a contingent right to receive one share of the Issuer's common stock.

3. Shares used to satisfy tax withholding obligations associated with the vesting of performance stock units on March 3, 2026.

Remarks:

	/s/Alice Givens, Power of Attorney	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.